Research

Hormonal

Adjunctive liraglutide 1.8 mg for 6 months following laparoscopic adjustable gastric banding (LAGB) provides no significant additional improvement in HbA1c or body weight compared to LAGB alone, and cessation of therapy leads to significant weight regain and worsening glycemic control relative to placebo.

If you have had a gastric band and are considering adding Liraglutide (Victoza) for 6 months, current evidence suggests it will not provide extra weight loss or blood sugar benefits during that time, and you may regain more weight after stopping it compared to not taking it. This does not rule out other GLP-1 drugs (like Semaglutide) or longer durations, but for this specific protocol, it is not recommended.

ModerateRefutesLOW confidence
Our pilot data suggest no additional improvement in glycaemic control or BW with LAGB and liraglutide therapy... at 12 months HbA1c was significantly higher in the liraglutide arm... at 12 months weight was significantly higher in the liraglutide arm
Cláudia Matta-Coelho et al. · International Journal of Obesity · 2023

Why this rating

Randomized placebo-controlled design, but significantly underpowered (n=27 vs target 58) and short duration (6 months treatment).

Source

Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial

Cláudia Matta-Coelho et al. · International Journal of Obesity · 2023

DOI 10.1038/s41366-023-01368-4

rct · n=27Cited 17×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →